Latancom

Timolol Maleate and Latanoprost, the active ingredients in Latancom, are a beta blocker and prostaglandin analog presented as eye drops for ocular use. The combination lowers intra‑ocular pressure and is indicated for glaucoma and ocular hypertension management.

GNH USA supplies Latancom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latancom is an ophthalmic combination that treats conditions associated with elevated intra‑ocular pressure.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Secondary open‑angle glaucoma: provides additional IOP reduction when monotherapy is insufficient.

Latancom may cause ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision shortly after instillation - Conjunctival hyperemia (red eye) - Dry eye or foreign‑body sensation - Increased eyelash length and pigmentation - Periocular skin darkening

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Persistent eye pain or inflammation - Sudden loss of vision - Irregular pupil dilation or iris pigmentation changes - Corneal edema or ulceration - Systemic bradycardia or hypotension

Before prescribing Latancom, clinicians should consider patient‑specific factors and monitor for adverse events. - Cardiovascular assessment: avoid in patients with severe bradycardia, heart block, or uncontrolled asthma/COPD. - Ocular history: contraindicated in active intra‑ocular inflammation or infection. - Allergy screening: do not use if hypersensitivity to timolol, latanoprost, or any excipients is known. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Monitoring: check intra‑ocular pressure regularly to assess therapeutic response. - Store at room temperature: keep in original container, protect from light and moisture.

Latancom can interact with systemic and ocular agents, altering efficacy or safety.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): additive bradycardia or hypotension. - Other prostaglandin analog eye drops: increased risk of ocular hyperemia and pigmentation changes. - Sympathomimetic agents (e.g., epinephrine eye drops): may diminish IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may increase corneal toxicity when used together. - Anticholinergic eye drops: possible alteration of pupil dynamics. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive IOP reduction, monitor pressure closely.